Sio Gene Therapies (SIOX) 10-Q2021 Q1 Quarterly report

Filed: 11 Aug 20, 6:45am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Abbott, Abbvie, abdominal, Acorda, Adjunct, Aid, amenable, anniversary, AST, bacteria, Basel, began, beneficiary, Bio, Biogen, blinded, Boston, brokerage, calling, cap, certiorari, Clarifying, compensatory, complementary, corridor, David, delisted, Denali, deploy, dimer, discharged, distancing, duly, Duopa, economy, elderly, epidemic, extinguishment, fewer, Fibrin, fundamental, GABA, GAD, GoCovri, gram, hereof, herewith, home, Inbrija, invasive, language, Leerink, Lysogene, magnitude, Medtronic, MeiraGTx, mid, Mitsubishi, modal, Nassif, NDA, neurosurgery, obsolete, pandemic, Passage, plateaued, port, prioritization, proactive, prove, PTC, quarantine, recession, redomicile, regular, remote, reopening, run, safer, screen, sequelae, sequester, spread, strain, sublingual, subset, Sunovion, surfaced, SVB, synuclein, Tanabe, Taysha, thereunto, transportation, undersigned, underway, uneconomic, unvested, uphold, vendor, Voyager, widespread, worsening, Wuhan

Removed: acceleration, acting, added, affirmative, allegedly, amortized, annum, assay, attrition, AXO, billed, borrowed, borrower, cerebrospinal, charter, collateral, composed, concurrent, consent, covenant, Cowen, customary, decentralization, declare, default, deposit, dispose, dissolution, eliminate, entry, exposed, forward, fringe, Gait, guarantor, HEADWAY, incurrence, indemnify, indexed, innervation, lender, lesser, lien, maturity, merger, MINDSET, morale, mutual, nonemployee, parent, percent, pilot, pledge, possession, prepay, prime, purpose, reached, readout, recipient, Reclassification, reclassify, remeasuring, repay, salary, secured, Serum, stranded, suffering, thereunder, underwritten, updated, utilized

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SIOX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Axovant Gene Therapies Ltd. (the “Company”) for the period ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Pavan Cheruvu, Principal Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 11, 2020	By:	/s/ Pavan Cheruvu
		Pavan Cheruvu
		Principal Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.